About Cytosolic carboxypeptidase 4
Cytosolic carboxypeptidase 4 (AGBL1) is a protein
from Homo sapiens identified by UniProt accession
Q96MI9, 1112 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | Cytosolic carboxypeptidase 4 |
|---|
| UniProt accession | Q96MI9 |
|---|
| Gene | AGBL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1112 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (49)
Diseases linked to this target (Open Targets).
- Fuchs endothelial corneal dystrophy · score 0.59
- alcohol consumption measurement · score 0.34
- neuroticism measurement · score 0.30
- partial thromboplastin time · score 0.25
- bitter alcoholic beverage consumption measurement · score 0.22
- anxiety measurement · score 0.21
- venous thromboembolism · score 0.21
- PHF-tau measurement · score 0.13
- cortical surface area measurement · score 0.06
- cortical thickness · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96MI9-F1 | alphafold | PREDICTED | 78.28 | — |
Amino-acid sequence (1112 residues)
MAEQEASGLQ VLLHTLQSSS DKESILTILK VLGDLLSVGT DRRIHYMISK GGSEALLQTL VDTARTAPPD YDILLPLFRL LAKVGLRDKK IGRKALELEA LDVTLILARK NLSHGQNLLH CLWALRVFAS SVSMGAMLGI NGAMELLFKV ITPYTRKRTQ AIRAATEVLA ALLKSKSNGR RAVNRGYVTS LLGLHQDWHS HDTANAYVQI RRGLLLCLRH IAALRSGREA FLAAQGMEIL FSTTQNCLDD KSMEPVISVV LQILRQCYPT SPLPLVTASS AYAFPVPGCI TTEPPHDLPE EDFEDDGDDE VDKDSDTEDG KVEDDDLETD VNKLSSKPGL DRPEEELMQY EVMCLELSYS FEELQSKLGD DLNSEKTQYA NHHHIPAAAS SKQHCYSKDQ SSCGQEREYA VQTSLLCRVK TGRSTVHLGS KKNPGVNLYQ NVQSNSLRRD SSESEIPDIQ ASPKADAWDV DAIFCPRMSA SFSNSTRTRE VVKVIDKLLQ THLKRVPFHD PYLYMAKARR TSSVVDFKMM AFPDVWGHCP PPTTQPMLER KCGVQRIRIF EDIRRLIQPS DVINKVVFSL DEPWPLQDNA SNCLRFFSKF ESGNLRKAIQ VREFEYDLLV NADVNSTQHQ QWFYFKVSGM QAAIPYHFNI INCEKPNSQF NYGMQPTLYS VKEALLGKPT WIRTGHEICY YKNHYRQSTA VAGGASGKCY YTLTFAVTFP HSEDVCYLAY HYPYTYTALM THLDILEKSV NLKEVYFRQD VLCQTLGGNP CPLVTITAMP ESNSDEHLEQ FRHRPYQVIT ARVHPGESNA SWVMKGTLEF LVSSDPVARL LRENFIFKII PMLNPDGVIN GNHRCSLSGE DLNRQWLSPS AHLQPTIYHA KGLLYHLSSI GRSPVVFCDF HGHSQKKNVF LYGCSIKETL WQAACTVGTS TILEEVNYRT LPKILDKLAP AFTMSSCSFL VEKSRASTAR VVVWREMGVS RSYTMESSYC GCNQGPYQCT QRLLERTKNE RAHPVDGLQG LQFGTRELEE MGAMFCLGLL ILELKSASCS HQLLAQAATL LSAEEDALDQ HLQRLKSSNF LPKHIWFAYH FFAITNFFKM NLLLHVSPVC DT
Explore Cytosolic carboxypeptidase 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets